- Home
- |
- About
- |
- Products
- |
- News and Media
- |
- Investors
- |
- Online Pharmacy
- |
- Contact Us
Medicure was founded in 1997 and became a public company in November 1999. As a U.S focused Specialty Pharma company with established sales of Aggrastat, Medicure carefully monitors opportunities within its own pipeline of products and possible strategic acquisitions in order to realize long-term value.
Medicure Inc. founded
MC-1 demonstrated potential in pre-clinical and Phase 1 studies
MC-1 meets primary and secondary endpoint of Phase 2 MEND-1 Clinical Trial
Positive results seen for MC-1 in MEND-CABG- 1 Phase 2 Trial meeting primary endpoint reducing CV death and MI by 37%
Acquired full U.S. rights to Aggrastat®
MC-1 did not meet the primary endpoint in the MEND-CABG II Phase 3 trial, largely due to an unexpectedly low event rate in the placebo group compared to MEND-CABG I
Leadership
Board of Directors
Our History
Mission and Values
Medicure Marks Its 25th Anniversary
People and Culture
Careers
AGGRASTAT® (tirofiban HCl) injection
Zypitamag®
Pipeline
Drug Safety
Medical Information
Patient Information
Events
Presentations / Conference Calls
Stock Information
Annual Reports
Quarterly Reports
Corporate Governance
Investor Contacts
Copyright © 2025 Medicure Inc. All Rights Reserved. | Privacy Statement